Cure8 research brief
The study suggests why a JAK1 inhibitor (filgotinib) may work better in some gut regions than others, offering a possible explanation for mixed clinical trial results in Crohn's disease. This could influence how future drugs are developed or tested for ileal versus colonic disease.
Clinicians treating Crohn's disease, researchers studying region-specific gut immunology or JAK inhibitors, and patients interested in how drug response may vary by disease location.
This abstract reports an ex vivo study using precision-cut intestinal slices (PCIS) from Crohn's disease patients to compare ileal versus colonic immune responses to the selective JAK1 inhibitor filgotinib.
The researchers found that colonic tissue showed strong T-cell–driven inflammation and was more responsive to JAK1 inhibition (reduced Th1/Th17 cytokines, oxidative stress, and STAT signaling), while ileal tissue showed innate/Th17-dominant inflammation and less sensitivity to filgotinib.
The piece is an abstract-level report from Journal of Crohn's & Colitis and reflects mechanistic/ex vivo findings rather than clinical trial outcomes.
This is an ex vivo mechanistic study (abstract-level) using human tissue slices, not a clinical trial; findings suggest hypotheses about region-specific drug responsiveness but do not establish clinical effectiveness. Filgotinib was the JAK1 inhibitor tested ex vivo; do not interpret this as a treatment recommendation.
Review the original publication for the complete reporting, methods, and context.
Funding disclosed by the source: ImmunAVATAR - 161L0247C; German Federal Ministry of Education and Research (BMBF); Fraunhofer Cluster of Immune Mediated Diseases (CIMD)
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The atlas maps which genes and cell types are different in Crohn's disease, offering clues about why inflammation persists and pointing to specific immune pathways (like JAK/STAT) that are already drug targets. The...
Scientists found BIRC3 gene changes that cause Crohn’s in some patients and showed those changes drive inflammation through the RIPK1/TNF pathway. That suggests a new, druggable pathway and may help predict who benefits...
This study identifies a specific genetic cause (BIRC3 variants) that drives inflammation through the RIPK1/TNF pathway and points to an existing drug target (RIPK1). If validated, the finding could help match patients to...
